Evidence map›Paper›PMID 30519925›Full record

ArticlePharmaceutical research2018

Aspherical and Spherical InvA497-Functionalized Nanocarriers for Intracellular Delivery of Anti-Infective Agents.

Arianna Castoldi, Martin Empting, Chiara De Rossi, Karsten Mayr, Petra Dersch, Rolf Hartmann, Rolf Müller, Sarah Gordon, Claus-Michael Lehr

Abstract read
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Nanomedicines for Infectious Diseases.Pharmaceutical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arianna CastoldiDepartment Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123, Saarbrücken, Germany.
Martin EmptingDepartment Drug Design and Optimization, HIPS, HZI, 66123, Saarbrücken, Germany.
Chiara De RossiDepartment Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123, Saarbrücken, Germany.
Karsten MayrDepartment Microbial Natural Products, HIPS, HZI, 66123, Saarbrücken, Germany.
Petra DerschDepartment Molecular Infection Biology, HZI, 38124, Braunschweig, Germany.
Rolf HartmannDepartment Drug Design and Optimization, HIPS, HZI, 66123, Saarbrücken, Germany.
Rolf MüllerDepartment Microbial Natural Products, HIPS, HZI, 66123, Saarbrücken, Germany.
Sarah GordonDepartment Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123, Saarbrücken, Germany. S.C.Gordon@ljmu.ac.uk.ORCID http://orcid.org/0000-0002-6263-3968
Claus-Michael LehrDepartment Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Center for Infection Research (HZI), 66123, Saarbrücken, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this work was to evaluate the potential of polymeric spherical and aspherical invasive nanocarriers, loaded with antibiotic, to access and treat intracellular bacterial infections.

methodsAspherical nanocarriers were prepared by stretching of spherical precursors, and both aspherical and spherical nanocarriers were surface-functionalized with the invasive protein InvA497. The relative uptake of nanocarriers into HEp-2 epithelial cells was then assessed. Nanocarriers were subsequently loaded with a preparation of the non-permeable antibiotic gentamicin, and tested for their ability to treat HEp-2 cells infected with the enteroinvasive bacterium Shigella flexneri.

resultsInvA497-functionalized nanocarriers of both spherical and aspherical shape showed a significantly improved rate and extent of uptake into HEp-2 cells in comparison to non-functionalized nanocarriers. Functionalized and antibiotic-loaded nanocarriers demonstrated a dose dependent killing of intracellular S. flexneri. A slight but significant enhancement of intracellular bacterial killing was also observed with aspherical as compared to spherical functionalized nanocarriers at the highest tested concentration.

conclusionsInvA497-functionalized, polymer-based nanocarriers were able to efficiently deliver a non-permeable antibiotic across host cell membranes to affect killing of intracellular bacteria. Functionalized nanocarriers with an aspherical shape showed an interesting future potential for intracellular infection therapy.

Indexed as

Adhesins, BacterialAnti-Bacterial AgentsBiological TransportCell LineDrug CarriersDysentery, BacillaryEpithelial CellsGentamicinsHumansKineticsLiposomesMicrobial ViabilityNanoparticlesParticle SizeShigella flexneriAdhesins, BacterialAnti-Bacterial AgentsDrug CarriersGentamicinsLiposomesAOT-gentamicinaspherical nanoparticlesbacteriomimetic nanocarriersintracellular infectioninvasin

Identifiers

PMID30519925
PMCPMC6290668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.